- Home
- Publications
- Publication Search
- Publication Details
Title
‘Acute myeloid leukemia: a comprehensive review and 2016 update’
Authors
Keywords
-
Journal
Blood Cancer Journal
Volume 6, Issue 7, Pages e441-e441
Publisher
Springer Nature
Online
2016-07-01
DOI
10.1038/bcj.2016.50
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
- (2016) D. A. Arber et al. BLOOD
- Gemtuzumab Ozogamicin Versus Best Supportive Care in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Unsuitable for Intensive Chemotherapy: Results of the Randomized Phase III EORTC-GIMEMA AML-19 Trial
- (2016) Sergio Amadori et al. JOURNAL OF CLINICAL ONCOLOGY
- Minimal residual disease evaluation by flow cytometry is a complementary tool to cytogenetics for treatment decisions in acute myeloid leukaemia
- (2016) María-Belén Vidriales et al. LEUKEMIA RESEARCH
- Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML
- (2015) Courtney D. DiNardo et al. AMERICAN JOURNAL OF HEMATOLOGY
- Characterization and prognostic features of secondary acute myeloid leukemia in a population-based setting: A report from the Swedish Acute Leukemia Registry
- (2015) Erik Hulegårdh et al. AMERICAN JOURNAL OF HEMATOLOGY
- Phase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome
- (2015) Paolo Strati et al. AMERICAN JOURNAL OF HEMATOLOGY
- International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts
- (2015) H. Dombret et al. BLOOD
- Targeting of folate receptor on acute myeloid leukemia blasts with chimeric antigen receptor-expressing T cells
- (2015) R. C. Lynn et al. BLOOD
- A phase I/II study of oral clofarabine plus low-dose cytarabine in previously treated acute myeloid leukaemia and high-risk myelodysplastic syndrome patients at least 60 years of age
- (2015) Sarah A. Buckley et al. BRITISH JOURNAL OF HAEMATOLOGY
- Cancer statistics, 2015
- (2015) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Final results of a phase 2 trial of clofarabine and low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia
- (2015) Tapan M. Kadia et al. CANCER
- Sorafenib Maintenance Appears Safe and Improves Clinical Outcomes in FLT3-ITD Acute Myeloid Leukemia After Allogeneic Hematopoietic Cell Transplantation
- (2015) Ahmad Antar et al. Clinical Lymphoma Myeloma & Leukemia
- A Phase I Study of Midostaurin and Azacitidine in Relapsed and Elderly AML Patients
- (2015) Brenda W. Cooper et al. Clinical Lymphoma Myeloma & Leukemia
- Favorable prognosis of biallelicCEBPAgene mutations in acute myeloid leukemia patients: a meta-analysis
- (2015) Hong-Ying Li et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Relation of Clinical Response and Minimal Residual Disease and Their Prognostic Impact on Outcome in Acute Myeloid Leukemia
- (2015) Xueyan Chen et al. JOURNAL OF CLINICAL ONCOLOGY
- Allogeneic Stem-Cell Transplantation in Patients With NPM1-Mutated Acute Myeloid Leukemia: Results From a Prospective Donor Versus No-Donor Analysis of Patients After Upfront HLA Typing Within the SAL-AML 2003 Trial
- (2015) Christoph Röllig et al. JOURNAL OF CLINICAL ONCOLOGY
- Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial
- (2015) Christoph Röllig et al. LANCET ONCOLOGY
- Clofarabine salvage therapy before allogeneic hematopoietic stem cell transplantation in patients with relapsed or refractory AML: results of the BRIDGE trial
- (2015) J M Middeke et al. LEUKEMIA
- CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia
- (2015) S S Kenderian et al. LEUKEMIA
- Incidences and Prognostic Impact ofc-KIT,WT1,CEBPA, andCBLMutations, and Mutations Associated With Epigenetic Modification in Core Binding Factor Acute Myeloid Leukemia: A Multicenter Study in a Korean Population
- (2015) Sang Hyuk Park et al. Annals of Laboratory Medicine
- Phase I Study of OPB-31121, an Oral STAT3 Inhibitor, in Patients with Advanced Solid Tumors
- (2015) Do-Youn Oh et al. Cancer Research and Treatment
- Acute myeloid leukemia: 2014 Update on risk-stratification and management
- (2015) Elihu H. Estey AMERICAN JOURNAL OF HEMATOLOGY
- High Doses of Daunorubicin during Induction Therapy of Newly Diagnosed Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis of Prospective Clinical Trials
- (2015) Qiang Gong et al. PLoS One
- Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation in Intermediate-Risk Acute Myeloid Leukemia Adult Patients in First Complete Remission: A Meta-Analysis of Prospective Studies
- (2015) Dandan Li et al. PLoS One
- Prognostic significance of FLT3 internal tandem duplication, nucleophosmin 1, and CEBPA gene mutations for acute myeloid leukemia patients with normal karyotype and younger than 60 years: a systematic review and meta-analysis
- (2014) M. Port et al. ANNALS OF HEMATOLOGY
- Phase I Trial of Maintenance Sorafenib after Allogeneic Hematopoietic Stem Cell Transplantation for Fms-like Tyrosine Kinase 3 Internal Tandem Duplication Acute Myeloid Leukemia
- (2014) Yi-Bin Chen et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Role of altered growth factor receptor-mediated JAK2 signaling in growth and maintenance of human acute myeloid leukemia stem cells
- (2014) A. M. Cook et al. BLOOD
- Differential impact of allelic ratio and insertion site in FLT3-ITD-positive AML with respect to allogeneic transplantation
- (2014) R. F. Schlenk et al. BLOOD
- 1LBA Clinical safety and activity in a phase I trial of AG-120, a first in class, selective, potent inhibitor of the IDH1-mutant protein, in patients with IDH1 mutant positive advanced hematologic malignancies
- (2014) D.A. Pollyea et al. EUROPEAN JOURNAL OF CANCER
- Targeting FLT3 to treat leukemia
- (2014) Heiko Konig et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials
- (2014) Robert K Hills et al. LANCET ONCOLOGY
- Hematopoietic cell transplantation in patients with intermediate and high-risk AML: results from the randomized Study Alliance Leukemia (SAL) AML 2003 trial
- (2014) J Schetelig et al. LEUKEMIA
- Comprehensive analysis of genetic alterations and their prognostic impacts in adult acute myeloid leukemia patients
- (2014) R Kihara et al. LEUKEMIA
- Role of genotype-based approach in the clinical management of adult acute myeloid leukemia with normal cytogenetics
- (2014) Antonia Cagnetta et al. LEUKEMIA RESEARCH
- Prevalence and prognostic significance of c-KIT mutations in core binding factor acute myeloid leukemia: A comprehensive large-scale study from a single Chinese center
- (2014) Ya-Zhen Qin et al. LEUKEMIA RESEARCH
- Crenolanib is a selective type I pan-FLT3 inhibitor
- (2014) C. C. Smith et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients ≤60 years with newly diagnosed acute myeloid leukemia
- (2013) Aziz Nazha et al. AMERICAN JOURNAL OF HEMATOLOGY
- Clofarabine doubles the response rate in older patients with acute myeloid leukemia but does not improve survival
- (2013) A. K. Burnett et al. BLOOD
- Sense and nonsense of high-dose cytarabine for acute myeloid leukemia
- (2013) B. Lowenberg BLOOD
- A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia
- (2013) S. H. Petersdorf et al. BLOOD
- Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation
- (2013) F. Ravandi et al. BLOOD
- Survival and cure of acute myeloid leukaemia in England, 1971-2006: a population-based study
- (2013) Anjali Shah et al. BRITISH JOURNAL OF HAEMATOLOGY
- Core binding factor acute myeloid leukemia: the impact of age, leukocyte count, molecular findings, and minimal residual disease
- (2013) Montserrat Hoyos et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Sorafenib in Combination With Intensive Chemotherapy in Elderly Patients With Acute Myeloid Leukemia: Results From a Randomized, Placebo-Controlled Trial
- (2013) Hubert Serve et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Study of Quizartinib Administered Daily to Patients With Relapsed or Refractory Acute Myeloid Leukemia Irrespective of FMS-Like Tyrosine Kinase 3–Internal Tandem Duplication Status
- (2013) Jorge E. Cortes et al. JOURNAL OF CLINICAL ONCOLOGY
- Optimization of Chemotherapy for Younger Patients With Acute Myeloid Leukemia: Results of the Medical Research Council AML15 Trial
- (2013) Alan K. Burnett et al. JOURNAL OF CLINICAL ONCOLOGY
- Allogeneic Transplantation Versus Chemotherapy as Postremission Therapy for Acute Myeloid Leukemia: A Prospective Matched Pairs Analysis
- (2013) Matthias Stelljes et al. JOURNAL OF CLINICAL ONCOLOGY
- DNMT3A mutation is a poor prognosis biomarker in AML: Results of a meta-analysis of 4500 AML patients
- (2013) Velizar Shivarov et al. LEUKEMIA RESEARCH
- Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
- (2013) NEW ENGLAND JOURNAL OF MEDICINE
- Targeted Inhibition of Mutant IDH2 in Leukemia Cells Induces Cellular Differentiation
- (2013) F. Wang et al. SCIENCE
- A novel STAT inhibitor, OPB-31121, has a significant antitumor effect on leukemia with STAT-addictive oncokinases
- (2013) F Hayakawa et al. Blood Cancer Journal
- Medicare Fee-for-Service Enrollees with Primary Acute Myeloid Leukemia: An Analysis of Treatment Patterns, Survival, and Healthcare Resource Utilization and Costs
- (2013) Juliana Meyers et al. Applied Health Economics and Health Policy
- A novel hierarchical prognostic model of AML solely based on molecular mutations
- (2012) V. Grossmann et al. BLOOD
- Sorafenib treatment of FLT3-ITD+ acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation
- (2012) C. H. Man et al. BLOOD
- Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial
- (2012) J. A. L. Yin et al. BLOOD
- Prognostic and therapeutic implications of minimal residual disease at the time of transplantation in acute leukemia
- (2012) S A Buckley et al. BONE MARROW TRANSPLANTATION
- Diversity of the juxtamembrane and TKD1 mutations (Exons 13-15) in the FLT3 gene with regards to mutant load, sequence, length, localization, and correlation with biological data
- (2012) Susanne Schnittger et al. GENES CHROMOSOMES & CANCER
- Prognostic Significance of the European LeukemiaNet Standardized System for Reporting Cytogenetic and Molecular Alterations in Adults With Acute Myeloid Leukemia
- (2012) Krzysztof Mrózek et al. JOURNAL OF CLINICAL ONCOLOGY
- Acute Myeloid Leukemia (AML): Different Treatment Strategies Versus a Common Standard Arm—Combined Prospective Analysis by the German AML Intergroup
- (2012) Thomas Büchner et al. JOURNAL OF CLINICAL ONCOLOGY
- Clofarabine Plus Cytarabine Compared With Cytarabine Alone in Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia: Results From the CLASSIC I Trial
- (2012) Stefan Faderl et al. JOURNAL OF CLINICAL ONCOLOGY
- Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia
- (2012) Hagop M. Kantarjian et al. JOURNAL OF CLINICAL ONCOLOGY
- High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses
- (2012) S K Metzelder et al. LEUKEMIA
- Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia
- (2012) Jay P. Patel et al. NEW ENGLAND JOURNAL OF MEDICINE
- FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo
- (2011) T. Sato et al. BLOOD
- Stat3 signaling in acute myeloid leukemia: ligand-dependent and -independent activation and induction of apoptosis by a novel small-molecule Stat3 inhibitor
- (2011) M. S. Redell et al. BLOOD
- Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse
- (2011) M. Levis et al. BLOOD
- Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia
- (2011) F. Buccisano et al. BLOOD
- Patterns of Molecular Response to and Relapse After Combination of Sorafenib, Idarubicin, and Cytarabine in Patients With FLT3 Mutant Acute Myeloid Leukemia
- (2011) Aref Al-Kali et al. Clinical Lymphoma Myeloma & Leukemia
- Prediction of Early Death After Induction Therapy for Newly Diagnosed Acute Myeloid Leukemia With Pretreatment Risk Scores: A Novel Paradigm for Treatment Assignment
- (2011) Roland B. Walter et al. JOURNAL OF CLINICAL ONCOLOGY
- Current findings for recurring mutations in acute myeloid leukemia
- (2011) Shinichiro Takahashi Journal of Hematology & Oncology
- Prognostic impact of c-KIT mutations in core binding factor acute myeloid leukemia
- (2011) Sang Hyuk Park et al. LEUKEMIA RESEARCH
- Cytarabine Dose for Acute Myeloid Leukemia
- (2011) Bob Löwenberg et al. NEW ENGLAND JOURNAL OF MEDICINE
- Therapy-related myeloid neoplasms: pathobiology and clinical characteristics
- (2010) H Sill et al. BRITISH JOURNAL OF PHARMACOLOGY
- Population pharmacokinetics of clofarabine and its metabolite 6-ketoclofarabine in adult and pediatric patients with cancer
- (2010) Peter L. Bonate et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Phase I study of sorafenib in patients with refractory or relapsed acute leukemias
- (2010) G. Borthakur et al. HAEMATOLOGICA
- Phase I/II Study of Combination Therapy With Sorafenib, Idarubicin, and Cytarabine in Younger Patients With Acute Myeloid Leukemia
- (2010) Farhad Ravandi et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase IIB Trial of Oral Midostaurin (PKC412), the FMS-Like Tyrosine Kinase 3 Receptor (FLT3) and Multi-Targeted Kinase Inhibitor, in Patients With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome With Either Wild-Type or Mutated FLT3
- (2010) Thomas Fischer et al. JOURNAL OF CLINICAL ONCOLOGY
- Effect of Complete Remission and Responses Less Than Complete Remission on Survival in Acute Myeloid Leukemia: A Combined Eastern Cooperative Oncology Group, Southwest Oncology Group, and M. D. Anderson Cancer Center Study
- (2010) Roland B. Walter et al. JOURNAL OF CLINICAL ONCOLOGY
- A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemias
- (2010) K W Pratz et al. LEUKEMIA
- A randomized phase I clinical and biologic study of two schedules of sorafenib in patients with myelodysplastic syndrome or acute myeloid leukemia: a NCIC (National Cancer Institute of Canada) Clinical Trials Group Study
- (2010) Michael Crump et al. LEUKEMIA & LYMPHOMA
- Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet
- (2009) H. Dohner et al. BLOOD
- Enhanced activation of STAT pathways and overexpression of survivin confer resistance to FLT3 inhibitors and could be therapeutic targets in AML
- (2009) J. Zhou et al. BLOOD
- The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes
- (2009) J. W. Vardiman et al. BLOOD
- Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in First Complete Remission
- (2009) John Koreth et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Phase II Study of Clofarabine Monotherapy in Previously Untreated Older Adults With Acute Myeloid Leukemia and Unfavorable Prognostic Factors
- (2009) Hagop M. Kantarjian et al. JOURNAL OF CLINICAL ONCOLOGY
- Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia
- (2009) Pierre Fenaux et al. JOURNAL OF CLINICAL ONCOLOGY
- Anthracycline Dose Intensification in Acute Myeloid Leukemia
- (2009) Hugo F. Fernandez et al. NEW ENGLAND JOURNAL OF MEDICINE
- A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome
- (2008) S. Faderl et al. BLOOD
- Mutant FLT3: A Direct Target of Sorafenib in Acute Myelogenous Leukemia
- (2008) Weiguo Zhang et al. JNCI-Journal of the National Cancer Institute
- Epigenetic regulation of signal transducer and activator of transcription 3 in acute myeloid leukemia
- (2008) Sampa Ghoshal (Gupta) et al. LEUKEMIA RESEARCH
- Mutations and Treatment Outcome in Cytogenetically Normal Acute Myeloid Leukemia
- (2008) Richard F. Schlenk et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More